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1. Introduction  
Gastrointestinal pathologies constitute among the most frequent form of disease in the 
World, especially enteric infections represent a significant burden of morbidity and 
mortality particularly in developing countries, where barriers between human feces and 
food and water supplies are inadequate. Enteric infections can be produce by a varied type 
of organisms, including bacteria, fungi, viruses and parasites. Among the parasites, two 
different types of them can produce gastrointestinal infections: helminths and protozoans. 
Inside the protozoans, these would be classified as flagellates (eg. Giardia intestinalis), spore-
forming or coccidia (eg. Cyclospora cayetanensis), ciliates (eg. Balantidium coli) and amebas (eg. 
Entamoeba histolytica). 
Amebas parasites include a large number of genuses and species among three subphyla of 
the phylum Amoebozoa: Conosa, Lobosa and Protamoebae. Pathogenic species are included in 
the families Achanthamoebidae (eg. Acanthamoeba), Vahlkampfia (eg. Naegleria), Balamuthiidae 
(eg. Balamuthia) and Entamoebidae (eg. Entamoeba histolytica). Entamoeba histolytica is the only 
recognized intestinal pathogenic ameba. Other species in the genus can be present in the 
human intestinal tract but are non-pathogenic (eg. E. dispar). 
Over the past decade, since it was formally recognized, through molecular biology and 
phylogenetic analyses, that Entamoeba histolytica and Entamoeba dispar were two distinct 
species, studies in this field have made dramatic in-roads into the understanding of E. 
histolytica and the pathogenesis of invasive amebiasis (Adams & MacLeod, 1977), which in 
fact represent a low proportion of the cases of amebiasis; most of then are asymptomatic. 
Given this knowledge an extensive understanding of the epidemiology, pathophysiology, 
and the molecular and genetic biology of the organism has been reached, improving not just 
the diagnosis, medical and surgical treatment options but, ultimately, the development of a 
safe and efficacious vaccine, which is actually in process (Bercu, et al 2007 ; Blessmann & 
Tannich, 2002 ; Gonzales, et al 2009). 
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2. Epidemiology 
In the last two decades too, it has also become clear that the true incidence of E. histolytica 
infection, particularly in vulnerable populations such as low socioeconomic children, is 
exceedingly high. Even more, in deprived areas of the World, especially in suburban and 
rural areas of the developing countries, particularly in tropical areas, amebiasis is a disease 
with a high burden of morbidity and mortality, with nations where prevalence estimates 
reach as high as 50% or more (eg. in Central and South America, Asia and Africa). However, 
this disease can be found worldwide and has been estimated that around 10% of the World’s 
population is infected. 
Morbidity from amebiasis represent around 40-50 million estimated cases per year in the 
World (World Health Organization, WHO). Although most cases are asymptomatic, 
dysentery and invasive extraintestinal disease can occur (Lysy, et al 1991). Amebic liver 
abscess is the most common manifestation of invasive amebiasis, but other organs can also 
be involved, including pleuropulmonary, cardiac, cerebral, renal, genitourinary, and 
cutaneous sites (Kenner & Rosen, 2006). Mortality due to amebiasis is estimated in 40,000-
100,000 deaths per year (WHO). Its lethality or case fatality ratio in amebic colitis is 
estimated in 2-10%, however would be increased up to 40% when amebic colitis evolves to 
fulminant necrotizing colitis or rupture (Aristizabal, et al 1991).  
Actually, amebiasis is the second leading cause of death from parasitic diseases worldwide. 
In many countries, the epidemiology of amebiasis has been recognized as a significant 
public health problem, even in many countries, before the 1990s, being overestimated and 
overdiagnosed due to the confusion between E. histolytica and E. dispar that many times 
generated a false positive diagnosis of amebiasis when incorrectly E. dispar infection was 
diagnosed as amebiasis due to E. histolytica. This happened because these species cannot be 
differentiated by direct examination, mainly by molecular techniques more often used these 
days.  
Although that today is still controversial of the role of E. histolytica in certain type of patients 
(eg. immunocompromised hosts, particularly in Human Immunodeficiency Virus, HIV 
infection/Acquired Immunodeficiency Syndrome, AIDS, but additionally in cancer and 
pregnant women). Additionally to this, has been stated that are certain groups of patients 
predisposed to amebic colitis: very young patients, malnourished subjects and recipients of 
corticosteroids, men who have sex with men and institutionalized individuals. Otherwise, 
race, sex and age, in general, do not affect significantly the epidemiology of disease. 
New contexts of disease include today the infection impact in transplant recipients (Franco-
Paredes, et al 2010). Infection due to Entamoeba histolytica can occur in transplant recipients 
leading to severe colitis and liver abscesses. 
Even more, in the context of globalization and migration, relevance of many gastrointestinal 
infections have been emphasised. Traveller’s diarrhoea represents 20-60% of the estimated 
incidence of illness during travel to developing countries, being 5-10% of its etiology due to 
protozoan agents. In this context, travel and migration from those countries with high 
prevalence of amebiasis have been also considered of risk for infection. Amebic liver 
abscesses have been reported in travel exposures as short as 4 days, with a median of 3 
months. Whereas amebic colitis is not common in short-term travellers (Cascio, et al 2011).  
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3. Pathology 
The causative protozoan parasite, E. histolytica (Figure 1), is a potent pathogen, transmitted 
via ingestion of the cystic mature form (Figure 2), the infective stage of this protozoan 
parasite (Dickson-Gonzalez, et al 2009).  
 
Fig. 1. Entamoeba histolytica throphozoites, showing nucleus and karyosoma (arrow) (HF, 
1000X) (Dickson-Gonzalez et al., 2009) 
Viable in the environment for weeks to even months, cysts can be found in fecally 
contaminated soil, fertilizer, or water or on the contaminated hands of food handlers and 
contaminated elements that can be used during food preparation or ingestion (Dickson-
Gonzalez, et al 2009).  
Fecal-oral transmission can also occur in the setting of anal sexual practices, for which some 
series have been found a higher incidence in men who have sex with men (MSM), or in the 
context of direct rectal inoculation through colonic irrigation devices.  
Excystation (Figure 2) occurs in the terminal ileum or colon (Figure 3), resulting in 
trophozoites, the invasive form.  
The trophozoites can penetrate and invade the colonic mucosal barrier, leading to tissue 
destruction, secretory bloody diarrhea, and colitis resembling inflammatory bowel disease. 
In addition, the trophozoites can spread hematogenously via the portal circulation to the 
liver or even to more distant organs, which would include lungs, brain, kidneys and skin, 
among others (extraintestinal disease) (Figure 2) (Dickson-Gonzalez, et al 2009).  
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Fig. 2. Life cycle of Entamoeba histolytica infection 
 
Fig. 3. Entamoeba histolytica throphozoites with a granulose cytoplasm (arrow), in the ileum 
producing an ulceration of the mucosa (HE, 200X) (Dickson-Gonzalez et al., 2009) 
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Fig. 4. Entamoeba histolytica throphozoites with abundant erythrophagia (arrows) (HF, 
1000X) (Dickson-Gonzalez et al., 2009) 
Today is well known that many pathogenic mechanisms are involved in the disease 
produced by this parasite, such as secreting proteinases that dissolve host tissues, killing 
host cells on contact, and engulfing red blood cells (Figure 4), leading to trophozoites to 
invade the intestinal mucosa, causing amebic colitis. Classically, the triad of Gal-lectin, 
cysteine proteinases and amoebapores of the parasite were thought to be the major proteins 
involved in the pathogenesis of amoebiasis (Accolla, 2006). 
Regard to the pathophysiology, new evidences regard the interaction between E. histolytica 
and human polymorphonuclear neutrophils (PMN) has been investigated, based on in vitro 
and in vivo animal studies, which have found that PMN actively migrate toward amebae 
trophozoite cells (Al-Mofleh, et al 1989; Arbo, et al 1993 ; Guerrant, et al 1981). Later studies 
in tissue culture systems demonstrated that PMN were confirmed to play a vital role in 
amebic tissue invasion mechanisms (Accolla, 2006; Arbo, et al 1993).  
Even more, at least axenic E. histolytica trophozoites and amebic protein preparations have 
been able to stimulate chemotaxis of human PMN in vitro. Additionally, E. histolytica inhibits 
the respiratory burst of PMN which represents a unique survival tactic and may contribute 
also to the pathogenesis of amebiasis (Dickson-Gonzalez, et al 2009).  
More recently, some evidence has being reported on the findings regard to this interaction in 
vivo on human beings. In a study on biopsy samples taken by endoscopic surgical 
procedures from individuals with amebic colitis assessed histopathologically the relation 
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between inflammatory infiltrating cells populations and the E. histolytica density in the 
intestinal lesions. PMN and lymphocytes are significantly associated with the extent of 
parasite presence (more significantly for PMN). Such findings support the theory that PMN 
interaction with E. histolytica contribute to the pathogenesis of lesions (Accolla, 2006). 
However, further studies are necessary in order to improve the knowledge of 
pathophysiology as well the systemic and local immune response of this worldwide public 
health problem which may cause potentially life-threatening diseases (Accolla, 2006 ; 
Adams, et al 1993 ; Jhingran, et al 2008).  
4. Gastrointestinal manifestations 
The most common presentation of amebic colitis is gradual onset of bloody diarrhea, 
abdominal pain, and tenderness spanning several weeks’ duration. Besides that, rectal 
bleeding without diarrhea can occur, especially in children. Other manifestations include 
heme-positive stools (seen in approximately 70-100%), diffuse abdominal tenderness (12-
85%), weight loss (40%), fever (10-30%) and anorexia. 
In the case of fulminant or necrotizing colitis, severe bloody diarrhea and widespread 
abdominal pain with evidence of peritonitis and fever are usually observed. Predisposing 
factors for this form of colitis include pregnancy, malnutrition, corticosteroid use and very 
young age (Hsu, et al 1995). 
 
Fig. 5. Colon mucosa with mixed inflammatory infiltrate and congestion with presence of E. 
histolytica (HE, 400X, in the zooming, 1000X) (Dickson-Gonzalez et al., 2009) 
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Colonic findings in amebiasis have varied from thickening of the mucosa to flask-shaped 
ulceration, mostly in the cecum or appendix or near the ascending colon, but rarely in the 
sigmoidorectal area. These intestinal lesions can include: a colonic mucosa with mixed 
inflammatory infiltrate and congestion with presence of E. histolytica (Figure 5), inflammatory 
infiltrate in the superficial epithelium of the colon, with absortive cells denudated (Figure 6), 
interglandular corion with abundant inflammatory infiltrate rich in PMN and eosinophils 
(Figure 7), erosions of colonic mucosa with fibrinousleucocitary exudate in the surface (Figure 
8), necrotic material and fibrinousleucocitary exudate (Figure 9) and the presence abundant 
eosinophils and edema in the interglandular corion (Figure 10). 
The development of fulminant colitis, ameboma, cutaneous amebiasis and rectovaginal 
fistulas can occur as medical and surgical complications of intestinal amebiasis (Kenner & 
Rosen, 2006 ; Lejeune, et al, 2009). 
5. Diagnosis 
Diferential diagnosis of amebiasis include a large list of infectious and non-infectious causes 
(Table 1). Then multiple studies can be performed to confirm or rule-out the diagnosis, 
including stools microscopy, cultures, antigen detection, histopathology, serology and 
molecular biology techniques (Dickson-Gonzalez, et al 2009). 
Microscopic evaluation using trichrome stain of stools is able to detect trophozoites in 
amebic colitis in 33-50%. Then serial stool samples (3) over no more than 10 days increase 
the sensitivity to 85-95%. Besides the trophozoite ingesting red blood cells, mostly 
happening in E. histolytica infection, leukocytes may be found (Burchard, et al 1993). 
At cultures infection diagnosis can be achieved in 50% to 70%. Culture is not a routine 
process and is less sensitive than microscopy in detection. Then, it should be understood 
that cultures of Entamoeba are primarily research tools rather than diagnostic ones. 
 
Differential diagnoses of amebiasis 
Infectious  Non-infectious 
Abdominal Abscess Arteriovenous Malformations 
Campylobacter Infections Diverticulitis 
Cholecystitis Hepatocellular Adenoma 
Echinococcosis Inflammatory Bowel Disease 
Escherichia coli Infections Ischemic Colitis 
Hepatitis A Perforated abdominal viscus 
Other Viral Hepatitis  
Pericarditis  
Peritonitis  
Pyogenic Hepatic Abscesses  
Right lower lobe pneumonia  
Salmonellosis  
Shigellosis  
Table 1. Differential diagnoses of amebiasis 
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Fig. 6. Inflammatory infiltrate in the superficial epithelium of the colon, absorptive cells are 
denudated (HE, 1000X) (Dickson-Gonzalez et al., 2009) 
Antigen detection through enzyme-linked immunosorbent assay (ELISA) is another test 
currently more available with multiple kits commercially available. In addition to it, kits 
using monoclonal antibodies against the GAL/GalNAc–specific lectin and the serine-rich 
antigen of E. histolytica yield an overall sensitivity up to 71%-100% and specificity up to 93%-
100% (Dickson-Gonzalez, et al 2009).  
Histopathological diagnosis of amebic colitis has been, until now, based on the 
demonstration of the amebic throphozoites in the histological sections, mostly without 
considering the environment of the parasite. However, cell populations such as PMN and 
eosinophils (Figure 6) would be predictive of the parasitic infection, which would change 
the diagnostic approach and criteria in the future. 
Serology is also another form of diagnosis for amebiasis. Multiple serologic assays are 
currently available, being the ELISA the most used of them. This, measures the presence of 
serum IgG antibodies antilectin. Its sensitivity is high for extraintestinal disease up to 98%, 
but very low for active amebic colitis particularly in endemic areas due repeated exposure 
and development of some immunity, limiting antibody-based testing for diagnosing 
currently active disease, since antibodies can persist for years after infection. Other 
techniques for extraintestinal disease available include immunofluorescent assay (IFA), 
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indirect hemagglutination (IHA) immunoelectrophoresis, counter-immunoelectrophoresis 
(CIE), immunodiffusion tests and complement fixation (CF) is less sensitive than other 
techniques.  
 
Fig. 7. Interglandular corion with abundant inflammatory infiltrate rich in PMN and 
eosinophils (HE, 400X, in the zooming 1000X) (Dickson-Gonzalez et al., 2009) 
Molecular biology techniques can directly identify RNA and DNA of the parasite, being 
specific for the species. Right now using multiple targeting genes, including a small-subunit 
rRNA gene (18S rDNA), serine-rich protein gene, chitinase gene, 30-kDa antigen gene, 
hemolysin gene, and extrachromosomal circular DNA, among others, E. histolytica can be 
differentiated from other species. Although that, its wide application is still very limited for 
the routine diagnosis given the cost as well the availability of facilities for these 
technologies.  
6. Treatment and prospects for a vaccine 
Additionally to the clinical, epidemiological and diagnostic issues, therapeutic management 
of amebiasis is currently showing new options. For amebic colitis the main choice drug is 
still metronidazole (given for 5 to 10 days). Treatment requires the use of two groups of 
antiparasitic drugs: luminal and tissue agents. Asymptomatic intestinal colonization with E. 
histolytica can be treated with luminal agents alone. Drugs used for the treatment of luminal 
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infections and generally prescribed for asymptomatic cyst passers include iodoquinol, 
diloxanide furoate, and paromomycin (5 to 20 days to eradicate colonization). Secnidazole 
has been used in some countries, but most studies coincide in that metronidazole, although 
more side effects such as headaches, anorexia, nausea, metallic taste, a disulfiram-like 
reaction to alcohol, and vomiting, is more effective than secnidazole. Recently some studies 
have also indicated a potential use of ivermectin for amebiasis (González-Salazar, et al 2009). 
In a systematic review published recently, information relating to the effectiveness and 
safety of the following interventions was described: diiodohydroxyquinoline (iodoquinol), 
diloxanide, emetine, metronidazole, nitazoxanide, ornidazole, paromomycin, secnidazole, 
and tinidazole.  
 
 
Fig. 8. Erosions of colonic mucosa with fibrinousleucocitary exudate in the surface (HE, 
400X) (Dickson-Gonzalez et al., 2009) 
Even more, in a recent review of the Cochrane Database Systematic Reviews, tinidazole was 
found as more effective in reducing clinical failure compared with metronidazole and has 
fewer associated adverse events. Combination drug therapy was found to be more effective 
in reducing parasitological failure compared with metronidazole alone. However, these 
results were based on trials with poor methodological quality so there is uncertainty in these 
conclusions. Further trials of the efficacy of antiamoebic drugs, with better methodological 
quality, are recommended.  
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The addition of broad-spectrum antibiotics to the treatment of acute amebic colitis may be 
appropriate if perforation is suspected. The possibility of coexisting bacteria causing 
dysentery must always be considered (Mackey-Lawrence & Petri 2011). Amebic colitis and 
some of its complications, such as ameboma, generally respond to medical treatment 
without surgical intervention, but for acute necrotizing colitis with toxic megacolon, partial 
or complete colectomy may be necessary.  
Although not currently a significant problem, is expected that in the future antiparasitic 
drug resistance can emerge as a threat in the therapeutic management of amebiasis. 
 
Fig. 9. Necrotic material and fibrinousleucocitary exudate (HE, 200X) (Dickson-Gonzalez et 
al., 2009) 
Recently, the genome of E. histolytica has been sequenced, which has widened the scope to 
study additional virulence factors. E. histolytica genome-based approaches have now 
confirmed the presence of Golgi apparatus-like vesicles and the machinery for glycosylation, 
thus improving the chances of identifying potential drug targets for chemotherapeutic 
intervention. Gal-lectin-based vaccines are under development, but additionally, promising 
vaccine targets such as serine-rich E. histolytica protein have yielded encouraging results. 
Considerable efforts have also been made to skew vaccination responses towards 
appropriate T-helper cell immunity that could augment the efficacy of vaccine candidates 
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under study. Thus, ongoing efforts mining the information made available with the 
sequencing of the E. histolytica genome will no doubt identify and characterize other 
important potential vaccine and drug targets and lead to effective immunologic strategies 
for the control of amebiasis.  
Over the past decade, progress in vaccine development has been facilitated by new animal 
models that allow better testing of potential vaccine candidates and the application of 
recombinant technology to vaccine design. Oral vaccines and DNA-based vaccines have 
been successfully tested in animals models for immunogenicity and efficacy.  
There has been significant progress on a number of fronts, but there are unanswered 
questions regarding the effectiveness of immune responses in preventing disease in man 
and, as yet, no testing of any of these vaccines in humans has been performed. In addition, 
there are strong economic barriers to developing an amebiasis vaccine and questions about 
how and where an effective vaccine would be utilized.  
 
 
 
 
 
Fig. 10. Abundant eosinophils and edema in the interglandular corion (HE, 1000X) (Dickson-
Gonzalez et al., 2009) 
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7. Conclusions 
Amebiasis has been recently suggested as one of the new proposed neglected tropical 
diseases (NTDs), beyond the original list. Neglected tropical diseases include in order of 
decreasing prevalence: soil transmitted helminths (these include roundworms such as 
Ascaris lumbricoides which causes ascariasis, whipworm which causes trichuriasis, 
hookworms which, depending on the species, cause necatoriasis and ancylostomiasis), snail 
fever (schistosomiasis), lymphatic filariasis, trachoma, kala-azar black fever (and other 
clinical forms of leishmaniasis), Chagas disease (american trypanosomiasis), leprosy, African 
sleeping sickness (human African trypanosomiasis), Guinea-worm (dracunculiasis), and 
Buruli ulcer. The World Health Organization (WHO) list of neglected tropical diseases is 
including the following additional diseases: cysticercosis, dengue and dengue haemorrhagic 
fever, echinococcosis, fascioliasis, onchocerciasis, rabies, yaws, podoconiosis and snakebites. 
Although its distribution is cosmopolitan, highest burden of amebiasis occurs in developing 
tropical countries, then, adding the low interest in research and in developing new drugs for 
its treatment, this pathology would be considered as neglected.  
Additionally to these considerations, right now is not just important in endemic countries, 
but also in and non-endemic ones, due to international migration, which makes now that 
amebiasis would represents a global phenomenon with a changing geography of its 
epidemiology.  
For all these reasons a high level of suspicion should be established into the medical practice 
not just in endemic countries in symptomatic and asymptomatic patients with 
epidemiological risk factors, but also in non-endemic countries in travellers and migrants 
from endemic countries. 
Early diagnosis and prompt treatment is highly important in an adequate resolution of 
disease and avoidance of extraintestinal pathology. More on, deep research is needed in 
different clinical and epidemiological settings such as in immunosupressed individuals. 
Fortunately recent insights into vaccine development promise potential candidates that 
would be effectively used in human beings in the next following years or decades, making a 
significant intervention into reduction of its high burden of morbidity and mortality 
especially in developing countries.  
8. Acknowledgements  
We would like to thank S. Dickson-Gonzalez for her review on the manuscript. 
9. References 
Accolla, R.S. (2006). Host defense mechanisms against pathogens. Surgical infections, Vol.7 
Suppl 2, pp. S5-7. 
Adams, E.B., MacLeod, I.N. (1977). Invasive amebiasis. I. Amebic dysentery and its 
complications. Medicine, Vol.56, pp.315-323. 
www.intechopen.com
 Colitis 
 
62
Adams SA, Robson SC, Gathiram V, et al. (1993). Immunological similarity between the 170 
kD amoebic adherence glycoprotein and human beta 2 integrins. Lancet, Vol.341, 
pp.17-19. 
Al-Mofleh, I.A., Al-Tuwaijri, A.S., Mahmoud, A.A., Alam, M. (1989). Entamoeba 
histolytica depresses chemiluminescence in stimulated human 
polymorphonuclear leukocytes. International journal of immunopharmacology, 
Vol.11, No.1, pp. 529-536. 
Arbo, A., Hoefsloot, M., Ramirez, A., Ignacio Santos J. (1993) Entamoeba histolytica inhibits 
the respiratory burst of polymorphonuclear leukocytes. Archivos de investigacion 
medica Vol.21, Suppl 1, pp.57-61. 
Aristizabal H, Acevedo J, Botero M. (1991). Fulminant amebic colitis. World journal of surgery, 
Vol.15, pp.216-221. 
Bercu TE, Petri WA, Behm JW. (2007). Amebic colitis: new insights into pathogenesis and 
treatment. Curr Gastroenterol Rep.; Vol. 9, pp.429-33. 
Blessmann, J., Tannich, E. (2002). Treatment of asymptomatic intestinal Entamoeba histolytica 
infection. N Engl J Med, Vol.347, No.17, pp.1384. 
Burchard GD, Prange G, Mirelman D. (1993) Interaction between trophozoites of Entamoeba 
histolytica and the human intestinal cell line HT-29 in the presence or absence of 
leukocytes. Parasitology research; Vol. 79, pp.140-145. 
Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G. (2011). The socio-ecology of 
zoonotic infections. Clin Microbiol Infect; Vol.17, pp.336-42. 
Dickson-Gonzalez SM, de Uribe ML, Rodriguez-Morales AJ (2009). Polymorphonuclear 
neutrophil infiltration intensity as consequence of Entamoeba histolytica density in 
amebic colitis. Surg Infect (Larchmt); Vol. 10, pp.91-7. 
Franco-Paredes C, Jacob JT, Hidron A, Rodriguez-Morales AJ, Kuhar D, Caliendo AM. 
(2010). Transplantation and tropical infectious diseases. Int J Infect Dis; Vol. 14, 
pp.e189-96. 
Gonzales ML, Dans LF, Martinez EG. (2009). Antiamoebic drugs for treating amoebic colitis. 
Cochrane Database Syst Rev; Vol. 2, pp.CD006085. 
González-Salazar F, Mata-Cárdenas BD, Vargas-Villareal J. (2009). Sensibility of Entamoeba 
histolytica trophozoites to ivermectin. Medicina (B Aires);69(3):318-20. 
Guerrant, R.L., Brush, J., Ravdin, J.I., et al. (1981). Interaction between Entamoeba histolytica 
and human polymorphonuclear neutrophils. The Journal of infectious diseases, 
Vol.143, No.2, (March 1981), pp. 83-93. 
Hsu YB, Chen FM, Lee PH, et al. (1995). Fulminant amebiasis: a clinical evaluation. Hepato-
gastroenterology; 42, pp.109-112. 
Jhingran A, Padmanabhan PK, Singh S, et al. (2008). Characterization of the Entamoeba 
histolytica Ornithine Decarboxylase-Like Enzyme. PLoS neglected tropical diseases;2: , 
pp.e115. 
Kenner BM, Rosen T. Cutaneous amebiasis in a child and review of the literature. Pediatric 
dermatology 2006;23: , pp.231-234. 
Lejeune M, Rybicka JM, Chadee K. Recent discoveries in the pathogenesis and 
immune response toward Entamoeba histolytica. Future Microbiol. 2009 
Feb;4(1):105-18. 
www.intechopen.com
 Amebic Colitis 
 
63 
Lysy J, Zimmerman J, Sherman Y, et al. Crohn's colitis complicated by superimposed 
invasive amebic colitis. The American journal of gastroenterology. 1991;86: , pp.1063-
1065. 
Mackey-Lawrence NM, Petri WA Jr. Amoebic dysentery. Clin Evid (Online). 2011 Jan 
13;2011. pii: 0918. 
Mann BJ, Torian BE, Vedvick TS, Petri WA, Jr. Sequence of a cysteine-rich galactose-specific 
lectin of Entamoeba histolytica. Proceedings of the National Academy of Sciences of 
the United States of America 1991;88: , pp.3248-3252. 
Pudifin DJ, Duursma J, Gathiram V, Jackson TF. Invasive amoebiasis is associated with the 
development of anti-neutrophil cytoplasmic antibody. Clinical and experimental 
immunology 1994;97: , pp.48-51. 
Rodríguez-Morales AJ, Barbella RA, Case C, Arria M, Ravelo M, Perez H, Urdaneta O, 
Gervasio G, Rubio N, Maldonado A, Aguilera Y, Viloria A, Blanco JJ, Colina M, 
Hernández E, Araujo E, Cabaniel G, Benitez J, Rifakis P. Intestinal parasitic 
infections among pregnant women in Venezuela. Infect Dis Obstet Gynecol. 
2006;2006:23125. 
Salata, R.A., Ahmed, P., Ravdin, J.I. (1989). Chemoattractant activity of Entamoeba histolytica 
for human polymorphonuclear neutrophils. The Journal of parasitology, Vol.75, pp. 
644-646. 
Salata RA, Martinez-Palomo A, Murray HW, et al. Patients treated for amebic liver abscess 
develop cell-mediated immune responses effective in vitro against Entamoeba 
histolytica. J Immunol. 1986;136: , pp.2633-2639. 
Salata RA, Ravdin JI. The interaction of human neutrophils and Entamoeba histolytica 
increases cytopathogenicity for liver cell monolayers. The Journal of infectious 
diseases 1986;154: , pp.19-26. 
Seydel KB, Li E, Swanson PE, Stanley SL, Jr. Human intestinal epithelial cells produce 
proinflammatory cytokines in response to infection in a SCID mouse-human 
intestinal xenograft model of amebiasis. Infection and immunity 1997;65: , pp.1631-
1639. 
Stanley, S.L., Jr. (2003) Amoebiasis. Lancet, Vol.361, No.1, (May 2003), pp. 1025-1034. 
Stanley SL Jr. Vaccines for amoebiasis: barriers and opportunities. Parasitology. 2006;133 
Suppl:S81-6. 
Stauffer, W., Ravdin. J.I. (2003). Entamoeba histolytica: an update. Current Opinion In Infectious 
Diseases, Vol.16, No.1, pp. 479-485. 
Tanyuksel M, Petri WA, Jr. Laboratory diagnosis of amebiasis. Clinical microbiology 
reviews 2003;16: , pp.713-729. 
Tsutsumi V, Mena-Lopez R, Anaya-Velazquez F, Martinez-Palomo A. Cellular bases of 
experimental amebic liver abscess formation. The American journal of pathology 
1984;117: , pp.81-91. 
Vega-Robledo GB, Leandro E, Silva R, et al. Effect of zinc-treated Entamoeba histolytica on the 
human polymorphonuclear respiratory burst. Archives of medical research 2005;36: 
, pp.75-79. 
www.intechopen.com
 Colitis 
 
64
Yu Y, Chadee K. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial 
cells without parasite-enterocyte contact. Gastroenterology 1997;112: , pp.1536-
1547. 
www.intechopen.com
Colitis
Edited by Dr Fukata
ISBN 978-953-307-799-4
Hard cover, 196 pages
Publisher InTech
Published online 05, January, 2012
Published in print edition January, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Inflammation of the colon is collectively called "Colitis". Since a variety of conditions may cause colitis and its
manifestations are similar among the causes, selection of the right treatment based on the correct diagnosis is
important in the management of this group of illnesses. Over the last few decades, a major shift has been
observed in the clinical attention to the pathogenesis of colitis from infectious to idiopathic inflammatory bowel
diseases. Colitis cases that are associated with chemical therapeutics and specific pathogens such as
amoeba, have become prominent in hospitalized individuals and immune deficient patients, respectively. In
addition, a great deal of progress has been made in colitis research triggering the need for updating our
knowledge about colitis. This book Colitis provides comprehensive information on the pathogenesis,
mechanism of resolution, and treatment strategies of colitis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
María Carolina Isea, Andre ́s Escudero-Sepulveda and Alfonso J. Rodriguez-Morales (2012). Amebic Colitis,
Colitis, Dr Fukata (Ed.), ISBN: 978-953-307-799-4, InTech, Available from:
http://www.intechopen.com/books/colitis/amebic-colitis
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
